Arrowhead Pharmaceuticals

This early-stage study is testing a new drug called ARO-DUX4 in adults and adolescents with FSHD1, a genetic muscle-wasting disease. The main goals are to see if the drug is safe, how the body processes it, and if it affects the target in the muscle. Participants will receive the…

This is an early-stage study to test the safety and body's response to a new drug called ARO-ATXN2 for adults with spinocerebellar ataxia type 2 (SCA2). Thirty-six participants will receive either a single dose of the drug or a placebo and be closely monitored. The main goal is t…

This study is testing whether an investigational drug called plozasiran can prevent painful and dangerous episodes of acute pancreatitis in adults with severely high blood triglycerides who have had pancreatitis before. About 288 participants will receive either plozasiran or a p…

This early-stage study is testing a new drug called ARO-INHBE for adults with obesity, including some who also have type 2 diabetes. Researchers want to see if the drug is safe and how it affects the body, particularly when taken alongside another weight-loss medication. The stud…

This early-stage study is testing a new drug called ARO-DM1 in adults with myotonic dystrophy type 1, a genetic disorder that causes progressive muscle weakness and stiffness. The main goal is to see if the drug is safe and how the body processes it. Researchers will also measure…

This early-stage study is testing a new drug called ARO-DIMERPA in adults with mixed hyperlipidemia, a condition involving high levels of both LDL ('bad') cholesterol and triglycerides. The main goal is to check if the drug is safe and how the body processes it, while also seeing…

This study aims to check the long-term safety and effectiveness of a drug called plozasiran for adults with very high levels of triglycerides, a type of fat in the blood linked to heart and pancreas problems. About 869 people who completed earlier related studies will receive an …

This study is testing an experimental injection called zodasiran to see if it can safely and effectively lower very high 'bad' cholesterol (LDL-C) in people with a rare, severe genetic condition called homozygous familial hypercholesterolemia (HoFH). It will involve about 60 part…

This early-stage study is testing a new drug called ARO-MAPT-SC to see if it is safe and how it behaves in the body. It will involve both healthy volunteers and people with early Alzheimer's disease. The main goal is to find a safe dose and understand the drug's effects before te…

This program provides access to an investigational drug called plozasiran for people with severe, hard-to-control high triglycerides. It is for adults and adolescents (15+) with a rare genetic condition (FCS) and for adults with high-risk severe hypertriglyceridemia (SHTG) who ha…

This early-stage study is testing a new drug called ARO-ALK7 to see if it is safe and how it affects the body in adults with obesity. Some participants will also take a common diabetes/weight loss medication (tirzepatide) to see if the new drug works alongside it. The main goal i…